Navigation Links
Leading Rehab Facility Urges Patients Not to Stop Taking Antidepressants After New Study Suggests Increased Risk of Heart Attacks and Strokes
Date:4/6/2011

MALIBU, Calif., April 6, 2011 /PRNewswire/ -- Cliffside Malibu, one of America's leading drug and alcohol treatment centers, is strongly urging its patients who are currently taking antidepressants not to stop, despite a new study and subsequent media reports that such drugs could raise the risk of heart attack or stroke in middle-age men taking the medications.  Cliffside is using e-mail, phone calls and face-to-face therapy sessions to encourage its patients who rely on those medications to continue doing so under close supervision by their psychiatrists.

"While the findings of this very preliminary study are interesting and should be taken seriously, we are strongly urging our patients to continue using antidepressants as prescribed," said Cliffside Malibu CEO Richard Taite.  "The immediate, serious risks to our patients were they to abruptly halt the use of antidepressants far outweigh potential adverse health effects."

A presentation at a cardiology conference earlier this week suggested antidepressants could lead to as much as a five percent increase in the thickness of the carotid artery.  The study's author, Dr. Amit Shah, has reportedly cautioned that the findings of the 513-person study are not enough to warrant taking patients off of antidepressants, and noted that depression elevates risk for heart disease.

"The symptoms of depression in our patients, many of whom suffer from mood and other disorders, are often acute and even life-threatening.  We are reaching out to every current and former patient to educate them and to ensure they make wise decisions in partnership with their physicians," added Taite.

About Cliffside Malibu

Cliffside Malibu is a full-service residential drug rehab and alcohol addiction treatment center in the Los Angeles area.  At Cliffside, highly trained experts administer individually tailored addiction rehabilitation programs for patients who place a premium on privacy, safety, and, most importantly, effectiveness.  The drug rehabilitation facility gets its name from its striking location, perched on a cliff overlooking the Pacific Ocean.  For more information, visit www.cliffsidemalibu.com or call 800-501-1988.  


'/>"/>
SOURCE Cliffside Malibu
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Leading Anti-Cancer Drugs: World Market Prospects 2011-2021
2. Hologic, Hospira, Boston Scientific, Allergan to Participate in Leading Medical Device Manufacturing Symposium
3. Newtech, Inc., a Leading Chinese EMS Patient Monitoring Company, Partners With Masimo to Incorporate rainbow® SET Noninvasive Measurement Capabilities Into New Patient Monitors
4. Leading Hospitals Committed to Healthcares Adoption of GS1 Standards Use Omnicell Solutions for Supply Chain Management
5. Life Technologies Initiates Clinical Trials Leading to 510(k) Submission of a Class I and Class II HLA Sequence-Based Typing Solution
6. Quest Diagnostics to Acquire Celera, Strengthening Position as Worlds Leading Innovator in Molecular Diagnostics and Development
7. First Varian High Dose Rate Brachytherapy Afterloader Supplied to Leading China Cancer Hospital
8. Two National Organizations Join DRIVE4COPD Movement to Raise Awareness of Nations Fourth Leading Cause of Death
9. PDI Announces Exclusive Partnership With Qforma, Leading Provider of Advanced Analytics for Health Sciences Industry
10. DJO Global to Acquire Leading Therapeutic Footwear Provider, Dr. Comfort
11. Reportlinker Adds The 2011 Top Ten Worlds Leading Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... EDMONTON, Alberta , July 21, 2017 ... the University of Alberta in Edmonton, ... Nature,s partner journal, Schizophrenia 1 , demonstrating that ... of schizophrenia with 74% accuracy. This retrospective analysis ... specific symptoms in schizophrenia patients with significant correlation, ...
(Date:7/20/2017)... PAUL, Minn. , July 20, 2017  Prime Therapeutics ... Jonathan Gavras , M.D., following today,s Institute for Clinical ... report on the effectiveness and value of abuse-deterrent ... manager on the policy roundtable at the meeting. ... is not a material cost benefit to the use of ...
(Date:7/14/2017)... , July 14, 2017 Endo International plc (NASDAQ: ... Tuesday, August 8, 2017.  Members of its senior management team will ... open at 8:30 a.m. ET. The dial-in number ... 497-0462, International (678) 509-7598, and the passcode is 45397076. Please dial ... A replay of the call will ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... ... Six greater Bay Area roller derby leagues are partnering with Brown Paper Tickets and the ... of blood drives in California, beginning July 29. Make ‘Em Bleed roller derby blood drives ... to have helped to save up to 2700 lives. , “The Make ‘Em Bleed blood ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... (ISPE) will host its 2017 Process Validation and Process Validation Statistics ... comprehensive solutions to process validation lifecycle challenges faced by process validation professionals ...
(Date:7/26/2017)... ... July 26, 2017 , ... A global ... in Jupiter. The state of the art center will provide advanced surgical ... a goal of providing heart patients longer lives. , North American Veterinary Heart ...
(Date:7/26/2017)... , ... July 26, 2017 , ... ... innovative specialty pharmacies, has released an updated version of the HCV Treatment Path ... for treating chronic hepatitis C virus (HCV) infection. All of the latest HCV ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... ... to announce the launch of their partnership to provide the Pharmacist eCare ... first pharmacy-focused platform in the country with the ability to develop the Pharmacist ...
Breaking Medicine News(10 mins):